[Detection and interpretation of PD-L1 in urologic neoplasms]

Zhonghua Bing Li Xue Za Zhi. 2025 Jan 8;54(1):11-15. doi: 10.3760/cma.j.cn112151-20241030-00714.
[Article in Chinese]

Abstract
in English, Chinese

Immune checkpoint inhibitors targeting PD-1/PD-L1 are gradually being applied in the treatment of advanced urinary system tumors. Immunohistochemical analysis of PD-L1 expression is the most popular method for screening suitable patients for immunotherapy and predicting therapeutic efficacy. The current application status of PD-L1 detection for urinary system tumors (mainly urothelial carcinoma), methods of the different antibody tests and the precautions, challenges and solutions in the interpretation of immunostaining were summarized in this review.

针对PD-1/PD-L1的免疫检查点抑制剂逐渐应用于晚期泌尿系统肿瘤的治疗实践，免疫组织化学检测PD-L1表达是筛选免疫治疗适宜人群和预测疗效的最常用方法。本文总结了泌尿系统肿瘤（主要为尿路上皮癌）PD-L1检测的应用现状、不同抗体检测方法及判读结果时的注意事项、常见问题和解决方案。.

Publication types

  • Review
  • English Abstract

MeSH terms

  • B7-H1 Antigen* / metabolism
  • Biomarkers, Tumor / metabolism
  • Carcinoma, Transitional Cell / diagnosis
  • Carcinoma, Transitional Cell / metabolism
  • Carcinoma, Transitional Cell / pathology
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunohistochemistry
  • Immunotherapy / methods
  • Urinary Bladder Neoplasms / diagnosis
  • Urinary Bladder Neoplasms / metabolism
  • Urinary Bladder Neoplasms / pathology
  • Urologic Neoplasms* / diagnosis
  • Urologic Neoplasms* / metabolism
  • Urologic Neoplasms* / pathology

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • Immune Checkpoint Inhibitors
  • Biomarkers, Tumor